Laser fabric cures skin diseases
The painless laser fabric will be the quickest device on the market at eradicating unwanted skin conditions.
IMAGE: A light-emitting cloth activates a photosensitizer to treat numerous skin conditions with nearly no pain. (Image credit: Texinov)
French scientists at Texinov (http://www.texinov.fr) have developed a knitted laser fabric that blasts the skin with light, giving treatment to enflamed skin or lesions over a 2 and a half hour appointment. Heralded as a miracle cure by users in clinical trials, the company says that the painless laser fabric will be the quickest device on the market at eradicating unwanted skin conditions, with no side effects.
Initially developed to improve the treatment of Actinic Keratosis--rough, scaly patches on the skin that develop from years of exposure to the sun--the light-emitting textile can treat and even cure a number of skin complaints such as acne, Paget's disease, psoriasis, and other disease like baby jaundice. Going by the name FLUXMEDICARE the new laser fabric was made in collaboration with a pan-European health consortium PHOS-ISTOS (http://www.phosistos.com/).
RELATED ARTICLE: Photonic cloth to fight jaundice in newborns
It works by covering the affected area with a photosensitizer cream and then wrapping the skin with the light-emitting textile. Optical fibers knitted into the fabric then speed up the reaction between oxygen and the cream beneath the skin.
Dr. Nadege Boucard, R&D GM at Texinov, explains, "FLUXMEDICARE is unprecedented in the field of treating skin conditions. Since the lighting textile wraps around the unique, individual contours of a patient, the emitted light in our device is the same at every part of the body under treatment, meaning the beams are homogenous."
Prior to FLUXMEDICARE the only technology used to treat skin ailments such as actinic keratosis came in the form of photodynamic therapy (PDT) where a patient would stand under a lamp blasted with light from a flat pane. With the intensity of the treatment, this previous technology would cause severe pain and even redness to the skin. "Previous PDT was unsatisfactory in many ways." Boucard adds, "Not only did patients report a pain ranking of at least 7/10 as well as burns and redness persisting for several days, but also, coming from a flat source, a lot of the emitted light was 'lost'."
During the clinical trials with INSERM Onco Thai Lab-CHRU Lille and Klinikum Vest in Germany, patients reported an average pain ranking on the FLUXMEDICARE device of between 0 and 1 out of ten. "The fact that we had a near 90% drop in pain levels compared to the previous technology, and the same efficacy was really promising. FLUXMEDICARE is easy to use for both the patient and the clinician: since you don’t need to be protected from the laser treatment, you can put your feet up and watch TV during the treatment," said Boucard.
For the medical team the new FLUXMEDICARE device comes relatively cheap. The old technology would cost anything from around $18,500 dollars for the lamp and protective gear and requiring a dedicated set up in a hospital room or within a dermatologist’s surgery. However, the new laser system currently costs around 1/3 of the price of its predecessor.
The PHOS-ISTOS consortium secured a grant of nearly $3 million dollars from the European Commission under the CIP funding program, and is comprised of participants from five European countries: (France) Institut National de la Sante et de la Recherche Medicale, Centre Hospitalier de Lille, EREO Sas, Ecole Nationale Superieure Arts Industries Textiles, Universite de Lille II – Droit et Sante, Deltaval Sarl; (Germany) Klinikum Vest Gmbh; (Finland) Fluence Theraputics OY, Modulight OY; (Italy) Consorzio per la Promozione della Cultura Plastica Proplast; (Netherlands) Reden B.V.
The team at PHOS-ISTOS expects to have their product ready for commercial uptake in April 2018.
SOURCE: Texinov; www.texinov.fr